FLAURA Findings, Emerging Combos Advance EGFR+ NSCLC Landscape
Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.
Source: OncLive